Low molecular weight heparin in COVID-19 patients prevents delirium and shortens hospitalization.
Neurol Sci
; 42(4): 1527-1530, 2021 Apr.
Article
in English
| MEDLINE | ID: covidwho-1130795
ABSTRACT
BACKGROUND:
COVID-19 patients present with delirium during their hospitalization.AIMS:
To assess the incidence of delirium in hospitalized COVID-19 patients and analyze the possible association with demographic, clinical, laboratory, and pharmacological factors.METHODS:
COVID-19 patients were assessed for clinical signs of delirium and administered the assessment test for delirium and cognitive impairment (4AT) and the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) scales.RESULTS:
Out of the 56 patients of our cohort, 14 (25.0%) experienced delirium. The use of low molecular weight heparin (LMWH) (enoxaparin 1 mg/kg/daily) was less frequent in patients with delirium (p = 0.004) and was accompanied by lower C reactive protein (CRP) levels (p = 0.006).DISCUSSION:
The use of LMWH was associated with absence of delirium, independently of comorbidities and age.CONCLUSIONS:
The use of LMWH may help preventing the occurrence of delirium in COVID-19 patients, with possible reduction of length of stay in the hospital and sequelae.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Enoxaparin
/
Heparin, Low-Molecular-Weight
/
Delirium
/
COVID-19
/
Anticoagulants
Type of study:
Cohort study
/
Observational study
/
Prognostic study
/
Qualitative research
Topics:
Long Covid
Limits:
Aged
/
Female
/
Humans
/
Male
Language:
English
Journal:
Neurol Sci
Journal subject:
Neurology
Year:
2021
Document Type:
Article
Affiliation country:
S10072-020-04887-4
Similar
MEDLINE
...
LILACS
LIS